Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study

2014260 citationsJournal Articlebronze Open Access

Authors

Damian Wild · University Medical Center Freiburg

Melpomeni Fani · University Hospital of Basel

Richard Fischer · Bausch Health (Germany)

Luigi Del Pozzo · University Medical Center Freiburg

Felix Kaul · University Medical Center Freiburg

Simone Krebs · University Medical Center Freiburg

Richard Fischer

Abstract

Treatment of neuroendocrine tumors with radiolabeled sst antagonists is clinically feasible and may have a significant impact on peptide receptor radionuclide therapy.

Topics & Keywords

Neuroendocrine Tumor Research Advances Radiopharmaceutical Chemistry and Applications Lung Cancer Research Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Nuclear Medicine

Volume 55, Issue 8, pp. 1248-1252

DOI: 10.2967/jnumed.114.138834

Field-Weighted Citation Impact: 14.17